Compound News and Research

RSS

Scientists uncover new mechanism that reduces risk of type 2 diabetes, cardiovascular disease

In a joint study, scientists from The Scripps Research Institute and the Dana-Farber Cancer Institute at Harvard University have uncovered a novel mechanism that dramatically increases insulin sensitivity and reduces the risk of developing type 2 diabetes and cardiovascular disease.

22 Jul 2010

Scientists discover world's first mass producible, low-cost organoclays for plastics

Scientists are reporting an in-depth validation of the discovery of the world's first mass producible, low-cost, organoclays for plastics. The powdered material, made from natural clay, would be a safer, more environmentally friendly replacement for the compound widely used to make plastics nanocomposites. A report on the research appears in ACS' Macromolecules, a bi-weekly journal.

22 Jul 2010

Affymetrix launches QuantiGene ViewRNA Assay formats

Affymetrix, Inc. today announced the launch of QuantiGene® ViewRNA Assay formats, which enable a new era of "in situ multiplex gene expression analysis" by allowing drug screening of native cells and advancing the pace of biomarker disease research and stem cell studies. These in situ assays enable researchers to visualize gene expression in individual cells at an unprecedented level of sensitivity and speed.

22 Jul 2010

Onconase, Amphinase 2 show positive results for SARS virus: Tamir Biotechnology

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases confirmed that testing of two (2) of the company's compounds Onconase (Ranpirnase), and recombinant Amphinase 2 showed positive in vitro results for Severe Acute Respiratory Syndrome, also known as (SARS) virus.

22 Jul 2010

Onyx begins Phase 3 trial of carfilzomib in combination with lenalidomide, dexamethasone for relapsed myeloma

Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.

22 Jul 2010

AMRI initiates enrollment for Phase I study of ALB-127158 for obesity

AMRI has commenced enrollment for a Phase I study of ALB-127158(a), a novel MCH1 receptor antagonist offering a potential new approach for the treatment of obesity. The announcement was made yesterday during a presentation by AMRI's Dr. Peter Guzzo, director, discovery research and development, at the 6th Obesity and Diabetes Drug Development Summit in Arlington, VA. Preclinical data were also reported.

21 Jul 2010

Pharmarama ranked as Britain's 8th fastest-growing private company for overseas sales

Pharmarama International, a leader in strategically sourcing comparator medicines for clinical trials worldwide, today announced that it has been ranked as Britain's eighth fastest-growing private company for overseas sales in a 2010 survey published by the country's leading business newspaper, The Sunday Times.

21 Jul 2010

Patent application for inexpensive CyPath assay filed by Biomoda

Cancer diagnostics company Biomoda,filed a U.S. patent application on a quantitative method for scoring cells labeled with the CyPath® assay to determine whether cells are dysplastic or carcinomic by measuring the photon emission rate.

21 Jul 2010

European marine and algae oil omega-3 ingredient market to grow at 10% CAGR to reach $525.6M in 2013

The flood of scientific evidence on omega-3 eicosapentaenoic acid/docosahexaenoic acid (EPA/DHA) has significantly buoyed the credibility of polyunsaturated fatty acids (PUFAs) as vital functional ingredients. Heightened consumer awareness has had a telling effect on the healthy growth charts of the marine and algae oil omega-3 ingredients market.

20 Jul 2010

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

A Phase 3 open-label study, recently published online by Pain Practice, has compared tapentadol extended release tablets, an investigational pain medication, to an existing prescription pain medication, oxycodone controlled release tablets.

20 Jul 2010

Pfizer suspends chronic low back pain, diabetic peripheral neuropathy studies in tanezumab clinical program

Pfizer Inc. today announced, at the request of the U.S. Food and Drug Administration (FDA), the suspension of the chronic low back pain and painful diabetic peripheral neuropathy studies in the clinical program for the investigational compound tanezumab. Investigation of the compound continues in some areas of high unmet medical need, including cancer pain.

20 Jul 2010

JANA Partners sends detailed critique of Charles River's revised investor presentation on WuXi acquisition

JANA Partners LLC today sent Charles River Laboratories International, Inc. a detailed critique of Charles River's revised investor presentation released earlier this week, in which Charles River once again seeks to persuade shareholders of the merits of its proposed acquisition of WuXi PharmaTech (Cayman) Inc..

17 Jul 2010

Florida Institute of Technology assists licensing CDNI-Glu compound to UK company

As a national research university, Florida Institute of Technology not only involves its students in research, but also seeks to license and patent its many innovations. An example of recently licensed university technology is a chemical compound that facilitates the work of neuroscientists in the laboratory.Associate Professor Nasri Nesnas was familiar as a chemist with the chemical compound CDNI-Glu, a commonly used laboratory research tool. Most often, neuroscientists use it to study the brain's neural networks by improving the localization of synaptic stimulation

17 Jul 2010

Resveratrol concentration impacts cancer risk mitigation: Study

Agricultural Research Service (ARS) chemist Thomas Wang, who specializes in cancer prevention research, has reported evidence that for some dietary compounds, length of exposure over time may be key to whether or not ingestion leads to a beneficial, or detrimental, effect.Scientists do not know exactly why one person develops cancer and another does not. But they do know that certain nutrients might increase or decrease cancer risk. There are "layers" of factors involved in the development of cancer, and Wang is studying the layers involving peoples' diet complexity and gene expression.

17 Jul 2010

Research findings may help identify human TOR kinase inhibitors

A parasite estimated to afflict as many as 12 million people worldwide relies on a family of genes that should make it vulnerable to compounds developed to treat cancer and other disorders, researchers at Washington University School of Medicine in St. Louis have found.

17 Jul 2010

ALOKA announces new ProSound F75 high-end color diagnostic ultrasound system

ALOKA CO., LTD., announced on July 16 the ProSound F75, a high-end color diagnostic ultrasound system of the new "F" series at its private exhibition, "Aloka Fair 2010." This new flagship of multi-purpose systems, providing unprecedented performance in a variety of clinical applications, is comfortable and easy to use.

16 Jul 2010

Scientists discover gene mutation responsible for CDG

An international team of scientists, led by researchers at the University of California, San Diego School of Medicine, has discovered the gene mutation responsible for a condition in which eye and brain development is severely disrupted in affected infants.

16 Jul 2010

Columbia scientists discover new way to alleviate chronic pain

Columbia scientists working to combat injury-related depression, substance abuse and suicide due to unremitting, persistent pain may have discovered a new way of treating that pain: a powerful analgesic dubbed N60 that leads to neither tolerance nor addiction.

16 Jul 2010

Noscira presents results of Nypta Phase IIa clinical trial for AD at ICAD 2010

Noscira, the Grupo Zeltia (ZEL.MC) subsidiary specialized in researching and developing drugs for treating neurodegenerative diseases, presented the results of a Phase IIa clinical trial of Nypta(R) (Tideglusib) on Alzheimer's disease (AD) at the International Conference on Alzheimer's Disease (ICAD), held in Honolulu (Hawaii) from July 10-15, 2010.

16 Jul 2010

New findings on macrophage activation can facilitate development of early diagnosis tools

Immune system cells called macrophages spring into action to surround and destroy threats such as viruses or cancer cells. But sometimes the would-be protective response leads to persistent inflammation, which, in turn, can cause disease.Scientists don't know exactly how macrophages cross the line from being good cops to bad cops, but researchers at the University of Florida recently unearthed several clues about the mechanisms involved. Through the lens of two inflammation-related diseases, HIV and rheumatoid arthritis, they identified changes in specific proteins linked to the action of macrophages, white blood cells that are key to the body's natural defenses.

16 Jul 2010

Compound News and Research

Scientists uncover new mechanism that reduces risk of type 2 diabetes, cardiovascular disease

Scientists discover world's first mass producible, low-cost organoclays for plastics

Affymetrix launches QuantiGene ViewRNA Assay formats

Onconase, Amphinase 2 show positive results for SARS virus: Tamir Biotechnology

Onyx begins Phase 3 trial of carfilzomib in combination with lenalidomide, dexamethasone for relapsed myeloma

AMRI initiates enrollment for Phase I study of ALB-127158 for obesity

Pharmarama ranked as Britain's 8th fastest-growing private company for overseas sales

Patent application for inexpensive CyPath assay filed by Biomoda

European marine and algae oil omega-3 ingredient market to grow at 10% CAGR to reach $525.6M in 2013

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

Pfizer suspends chronic low back pain, diabetic peripheral neuropathy studies in tanezumab clinical program

JANA Partners sends detailed critique of Charles River's revised investor presentation on WuXi acquisition

Florida Institute of Technology assists licensing CDNI-Glu compound to UK company

Resveratrol concentration impacts cancer risk mitigation: Study

Research findings may help identify human TOR kinase inhibitors

ALOKA announces new ProSound F75 high-end color diagnostic ultrasound system

Scientists discover gene mutation responsible for CDG

Columbia scientists discover new way to alleviate chronic pain

Noscira presents results of Nypta Phase IIa clinical trial for AD at ICAD 2010

New findings on macrophage activation can facilitate development of early diagnosis tools

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News